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Peptide Sequence Retrieved from The Red Sea Metagenomics Library

Abstract
Cancer is imposing a worldwide health concern with alarming morbidity and mortality
rates. Its burden stems from its increasing incidence along with depletion of efficient
therapeutic options. Current conventional anticancer therapies; surgery, radiotherapy
and chemotherapy are barely effective with deleterious side effects that ruin patients'
quality of life. There is a paradigm shift in the interest of pharmaceutical industry
towards a new class of peptide based drugs offering more selectivity, easier synthesis,
wider safety profile and lower cost of manufacture. Anticancer peptides (ACPs) have
gained interest in the last few decades due to their intrinsic properties such as
cationicity and small size enabling them to be selective and effective anticancer agents.
In our study, we made use of the publicly available databases of ACPs and the Red Sea
metagenomics data, generated during AUC/KAUST Red Sea microbiome project. Our
experimental design consists of two phases; in silico analysis followed by in vitro
validation of the computational results. In silico analysis resulted in a set of peptide
hits from our library that share similar composition to ACPs. One hit was submitted for
further in silico prediction of structure and function. The sequence was then chemically
synthesized for subsequent in vitro functional assessment through cytotoxicity assay
(MTT assay), apoptosis/necrosis detection assay (Annexin/PI assay) and RNA
expression analysis of Caspase 3.The cancer cell lines used were U2OS, HepG2,
MCF7 and HeLa. The peptide showed evident, yet variable, dose dependent
cytotoxicity in all tested cell lines. Membranolysis and Apoptosis could be concluded
as possible mechanisms of action from the results of annexin assay and RT-PCR that
showed overexpression of Caspase 3 in peptide treated U2OS cells. Our results, despite
being consistent and in line with each other, more investigative techniques should be
done for confirmation and elucidation of the molecular mechanism of action of our
peptide lead.
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Chapter 1
Literature review & Study objectives

1.1. Literature review:

1.1.1. Cancer burden:
There is no debate over the health and economic burdens that cancer yields both at the
patient and community levels in developing and developed countries as well. Cancer
encompasses a large group of diseases affecting any organ of the body causing
uncontrollable cellular proliferation that is commonly metastasizing far from its
original tissue and resisting treatment ("What Is Cancer?", 2016).
Cancer incidence is not restricted to any age group, gender or race. Cancer related
mortality rate is surpassing cardiac disease related one within the coming few years.
According to World Health Organization (WHO) and International Agency of
Research on Cancer (IARC), there were 14.1 million new cancer cases, 8.2 million
deaths and 32.6 million people living with cancer worldwide in 2012 with expectancy
of the annual incidence rate to rise to 22 million cases before 2030 (de Martel et al.,
2012).
Current cancer treatments include surgery, chemotherapy, radiotherapy and the
recently introduced immunotherapy and biologics. The limited efficiency of current
conventional onco-therapeutic options together with emerging resistance of cancer
cells to a wide range of chemotherapeutic drugs add up a recent challenge to the
burden of cancer (Chen et al., 2014).
Surgery is still the primary treatment approach for most solid malignancies.
However, some tumors are inoperable due to anatomical inaccessibility, aggressive
tumor nature invading adjacent tissues or risk of injury to a nearby vital unaffected
structure. Radiotherapy is restrained in practical use by a certain exposure dose limit
beyond which normal tissues are wrecked (Riedl et al., 2011).
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The problem with chemotherapy, despite its relative efficacy especially for
advanced cases, stems from its uncontrolled bio-distribution and lack of effective
selection of malignant cells rather than normal cells. This treatment option is said to
transform a deadly cancer into a chronic disease with more survival years, slower
clinical deterioration and evident side effects such as bone marrow suppression,
alopecia and mucositis which all interfere with patients' quality of life (Riedl et al.,
2011).
Moreover, cancer cells developed several multiple drug resistance (MDR)
mechanisms that enabled them to tolerate those chemotherapeutic drugs rendering
many cancers resistant to therapy (Perez-Tomas, 2006). Given all these drawbacks of
the available cancer treatment options in a time where the number of cancer victims is
increasing every day, is an alarm for the need of a new alternative stand-alone or
adjuvant cancer therapy. Such a new therapy should be of comparable efficacy if not
higher and with a wider safety profile.

1.1.2. Peptide based drugs:
The pharmaceutical industry is in continuous search for drug lead molecules that are
of high potency, paramount safety and low manufacture cost. During the last few
decades, peptides were mined for new lead competitors in the pharmaceutical market.
Most drugs entering the market during the 20th century were developed in what can be
called "chemistry dominated era". Those drugs are almost all small molecule drugs
with a molecular weight cutoff of 500 daltons (Newman &Cragg., 2012).
The small size of such drugs grants them adequate oral bioavailability, efficient
membrane permeabilization, metabolic stability and low cost of synthesis. On the
other hand, this small size renders them non target selective causing side effects.
Protein based drugs or biologics e.g. insulin and monoclonal antibodies have been
introduced with the advance in molecular biology tools and recombinant protein
expression technology in the latter half of the 20th century. Their large size (>5000
daltons) renders them finely specific for their targets on the cost of inadequate
membrane permebailization, high cost of synthesis, poor oral bioavailability and
metabolic instability, (Craik et al., 2013).
2

Peptide leads have been the focus of the pharmaceutical R&D process because they
simply fill the gap in molecular weight and properties between small molecule drugs
and protein biologics. Like biologics, they can bind with high specificity to their
molecular targets with few side effects. Their smaller size makes them more
membrane penetrable, less immunogenic and more amenable to chemical synthesis
with lower cost of manufacture than biologics (Craik et al., 2013, Uhlig et al., 2014).
Furthermore, they display a broad range of targets due to multiple mechanisms of
action. They are less toxic than small molecules due to low accumulation in tissues
because of their susceptibility to proteolytic degradation. Being discoverable from
various natural sources along with their structural and biological diversities offer a
rich source for peptide drug lead design and development. Finally, they are amenable
to site specific modifications which make them good candidates for tailored dugs with
desired therapeutic properties in the era of personalized medicine (Craik et al., 2013).
This paradigm shift in pharmaceutical interest towards peptides is hindered by
some technical and financial challenges. Large scale peptide synthesis still needs
cheaper methods to be developed. Natural peptides typically possess poor absorption,
distribution, metabolism and excretion (ADME) properties. Methods to modify
peptides to overcome their low systemic availability and high clearance still need to
be optimized. Cyclizations, L-aa substitution with D-aa and modification of N &C
termini have shown some desirable effects on peptide stability (Craik et al., 2013, Di,
2015).
Many peptide drugs have been in the market for decades representing 2% of the
drug market e.g. Cyclosporin-A (CS-A) (11- aa) as an antifungal and
immunosuppressant agent. Many others are still in the preclinical and clinical stages
of the drug development pipeline. Others are still under basic research such as the
Anticancer peptides (ACPs) (Di , 2015)
Accommodating new chemical and molecular biology tools and skills to efficiently
design and optimize peptide based drug leads is becoming increasingly essential.
Nonetheless, it mustn't be ignored that developing statistical and in silico models for
exploitation of the publicly available databases of current knowledge about peptide
drugs and for predicting their properties prior to synthesis would greatly enhance the
next wave of peptide drug leads (Uhlig et al., 2014).
3

1.1.3. Anticancer peptides (ACPs):
The attention to peptides as potential anticancer agents was drawn from some studies
of antimicrobial peptides (AMPs) showing varying degree of activity against tumor
cells (Hoskin &Ramamoorthy, 2008). The interest in understanding AMPs arouse in
order to develop new alternative resistance-free antimicrobial therapies after the
illegitimate use of antibiotics in the last 50 years inducing a worldwide problem of
microbial resistance (Reddy, Yedery, & Aranha, 2004).
Antimicrobial peptides constitute one of the weapons of innate immunity in almost
all eukaryotes. They are small molecules of low antigenicity. Generally, AMPs are
cationic, amphipathic with a high proportion of hydrophobic residues. The ability of
these small cationic molecules to disrupt bacterial membranes depends on their
biophysical properties such as their amphipathicity, hydrophobicity, size, secondary
structure and most importantly the non-specific electrostatic interaction with the
anionic lipid rich microbial membrane (Huang et al., 2014).
The rapid non-specific mechanism of membrane permeation and subsequently cell
death offers marked potency, selectivity and abrupt changes that the cell machinery
can't simultaneously endure to produce a resistant membrane (Chen et al., 2014).
AMPs, either natural or synthetic, didn't only show activity against bacterial cells but
their activity was also reported against fugal, protozoal, viral and cancer cells (Gaspar,
Veiga, & Castanho, 2013).
Anticancer peptides (ACPs) exert their cytotoxic activities in a similar way to
AMPs. AMPs and ACPs share the same biophysical properties knowing that most
ACPs are originally AMPs or synthetic AMP analogs. The increased net surface
negative charge is a shared molecular feature of bacterial and tumor cells, relative to
healthy normal cells. Hence, ACPs and AMPs can also be said to share the same
molecular principle of cytotoxicity and selectivity (Gaspar, Veiga, & Castanho, 2013).
The ability of ACPs to selectively recognize and lyse tumor cells is still researched
for the mechanistic details of the cellular death event. Kinetics of cancer cell killing
involve membranolytic and non-membranolytic modes of action. However, the nonreceptor mediated membrane lysis events still best explain the rapid and selective
ACPs induced cytotoxicity (Epand, n.d, 2016).
4

In 2009, Iwaski et al. provided a proof of the role of phosphatidyl serine (PS)
density, a main lipid component of cancer cell membrane, to anticancer activity of
ACPs stressing on the proposed concept of electrostatic interaction (Iwaski et al.,
2009). Other membrane features that aid ACP cytotoxicity are increased membrane
fluidity allowing easy destabilization of the membrane along with its increased
surface area due to more numerous microvilli allowing exposure to higher number of
ACP molecules (Sok et al., 2002).
There are different modes of action that can explain the mechanism of membrane
disruption. It occurs either through pore formation (torroidal and barrel stave model),
thinning and membrane dissolution (detergent-like Carpet model), lipid peptide
domain formation or membrane depolarization (Fig.1) (Papo & Shai, 2005).
Membranolysis involves mitochondrial membrane disruption as well releasing
initiators of apoptosis which can explain the late death events with some ACP
examples (Constance &Lim., 2012).
From a structural point of view, there is an evident structural diversity in the AMPs
and ACPs studied up till now. Certain ACP specific aa and dipeptide composition
frequency is observed as well (Tyagi et al., 2013). The conformation of most ACPs
fall either into the α-helical (e.g. Cecropins) or the β-sheet structure (e.g. Defensins).
Structure activity relationship (SAR) studies so far have demonstrated that peptidemembrane interaction depends on and affects the 2ry structure acquired by the
peptide.

Figure 1: Various models of membrane permeation by ACPs. Adapted with
permission from/: http://crdd.osdd.net/raghava/anticp.
5

Wang and Zhang found that the α-helical conformation of MPI-1, a synthetic
analog of the AMP Polybia-MPI extracted from Polybia Paulista wasp venom, was
essential for its membranolytic anticancer activity (Wang et al., 2008, wang et al.,
2009b, Zhang et al., 2010). In 2014, Chen et al. designed a series of α-helical cationic
peptides with certain (IIKK) repeats that promoted α-helical conformation upon
interaction with the negatively charged membranes. They found out that the α-helical
conformation with a certain hydrophobic effect is essential for membrane
permeablization. Peptides then got internalized initiated an apoptotic cascade (Chen et
al., 2014).
Membrane disruption events are not always ensued with an apoptotic event.
Dermaseptin B2, from tree frog Phyllomedusa bicolor , was found to induce some
necrotic mechanisms following membrane lysis. That was confirmed through
increased release of lactate dehydrogenase (LDH), propidium iodide (PI) staining and
morphological studies using confocal microscopy (Van Zoggel., et al., 2012).
CAMEL peptide, a synthetic hybrid peptide derived from the natural Hyalophora
cecropia AMP; cecropin and Apis mellifera AMP; mellitin, is a necrosis inducing
peptide that showed statistically significant in vivo tumor regression and relapse delay
when combined with an Interleukin-12 carrying plasmid (Smolarczyk et al., 2010).
The direct membrane disrupting effect is not always the trigger for cell death
induced by ACPs. LcfinB, isolated from cow's milk, is a known ACP that induces
membrane pore formation with subsequent loss of membrane integrity and peptide
internalization. LcfinB-induced membrane damage caused necrosis of human
neuroblastome and mouse fibrosarcoma cells (Eliassen et al., 2006). On the other
hand, LcfinB induced reactive oxygen species (ROS) generation and subsequent
mitochondrial mediated apoptosis in human breast and leukemia cells (Mader, 2005).
Human neutrophil peptides 1-4 (HNPs 1-4) are a group of defensive peptides
(Defensins) released from the neutrophils in response to microbial infections. Their
anticancer properties have been investigated for a long time. HNP-1 was found to
have dual mechanism of action through damaging cell membrane and causing DNA
strand break (Gera and Lichtenstein, 1991). That was recently confirmed as a
mechanism of action in prostate cancer cells (Gasper et al., 2015). On the other hand,
Wang et al. reported that expressing HNP-1 in breast and colon cancer cells induced
6

cellular death via recruiting dendritic cells eliciting an immune response (Wang et al,
2009c).
Other non-membranolytic mechanisms of ACPs include inhibition of tumor
neovascularization (Koshimaki et al., 2009). Leuschner et al. used a 15 aa segment
derived from chorionic gonadotropin as a mechanism for targeting cells expressing
receptors for chorionic gonadotropin/Luteinizing hormone (CG/LH) in hormone
dependent prostate and breast cancer respectively (Leuschner, 2005). Different
mechanisms of ACPs are demonstrated in figure 2.
The different potencies and mechanisms of action adopted by the same peptide in
different types of cancers can be explained by the differential expression pattern of
negatively charged lipid molecules on the surface of different neoplastic cells which
might condition the engagement and conformation of the interacting peptide dictating
its preference to kill specific cancer cells. This elucidates the possibility that the
mechanism of action depends on the cell type (Eliassen et al., 2006, Gasper et al.,
2015).

Figure 2: Different mechanisms of action of ACPs. ACPs' activity can be due to a
membranolytic mechanism, followed by apoptosis or necrosis, or a nonmembranolytic mechanism such as a mediated immune response or DNA synthesis
inhibition. Adapted and modified from (Gaspar, Veiga, & Castanho, 2013).
7

The future of peptides as an oncotherapy is still met by some challenges. The
concept of peptides being amenable to sequence manipulation during synthesis in
order to end up having certain structural conformation and biophysical properties
should be dealt with caution to have balanced equilibrium between different
characters and maintaining potency and selectivity (Gaspar, Veiga, & Castanho,
2013).
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1.2. Study Objectives:
This study had two main objectives:
1. Computational scanning of the Red Sea metagenomics library, created during
AUC/KAUST Red Sea expeditions in 2008 & 2010, for sequence hits that show
composition similarity to known experimentally verified ACPs. Computational
structure and function prediction of one hit that shows adequate score and properties
and presumably would act as an anticancer peptide (ACP).
2. Validation of the in silico results through in vitro experiments that would prove or
deny the in silico result using chemically synthesized peptide hit. Experiments include
cytotoxicity assay (MTT assay) against 4 cancer cell lines and one normal cell line,
apoptosis and necrosis detection assay (Annexin/PI assay) and RNA expression
analysis (RT-PCR) of Caspase 3; a known apoptosis marker.

9

Chapter 2
Materials & Methods:
2.1. Computational Analysis:
2.1.1. Red Sea Metagenomics Library scanning:
Scanning the Red Sea Metagenomics library, created at AUC after the Red Sea
expedition in spring 2010 in collaboration with KAUST, was inherited after Tyagi et
al. (Tyagi et al., 2013). Positive and negative examples of ACPs were required. One
set of experimentally validated ACPs was retrieved from publicly available AMP
databases such as the antimicrobial databases (APD) and (APD2) (Wang, 2004, Wang
et al., 2009a), the collection of antimicrobial peptides (CAMP) (Waghu et al., 2014)
and the database of Anuran defense peptides (DADP) (Novkovic et al., 2012).
Another set of AMPs with no known anticancer activity was recruited, from the same
databases, for comparison.
A preliminary investigation of all possible one amino acid (aa) and oligopeptide
frequencies was done for the 2 datasets. Certain 1 aa and dipeptide (2 aa) frequencies
were naturally observed in each dataset, creating a narrow standard error from their
mean, indicating that the reported frequencies are almost consistent within each
dataset. Thus, one aa and 2 aa composition were used as input features when
comparing the 2 datasets for selecting only those recognizing ACPs (t- test, p < 0.05,
Bonferroni multiple testing correction). A sliding window of an increasing size
(minimum 5 aa) was used to generate peptides from metagenomic reads and
assemblies. Each generated peptide had the ACPs' specific amino acid and dipeptide
frequencies measured and scored accordingly.
A set of 59 peptide sequences with various scores and lengths was generated.
Furthermore, the generated peptides were searched for Hidden Markov Models
(HMMs) (Eddy, 1998) confirmed for the experimentally validated ACPs. Then, they
were fed into an online tool "AntiCP" (Institute of microbial technology, Chandigarh,
India) for confirming their prediction as ACPs (http://crdd.osdd.net/raghava/anticp)
(Tyagi et al., 2013).
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Out of the 59 sequences, a homeodomain sequence (PF00046.24) of 30 aa was
chosen for synthesis. A short sequence (AAEK), corresponding to 2 Alanines,
Glutamate and a Lysine, was added to the 30 aa homeodomain peptide sequence
outside the HMM domain as a means to increase its hydrophobicity and charge and
hence

its

penetrability.

The

new

34

aa

sequence

(AAEKEFIKYPYPTPLQYQQLATRLKVEKKLVRRW) was again validated as an
ACP

using

AntiCP

webserver

provided

by

(Tyagi

et

al.,

2013)

(http://crdd.osdd.net/raghava/anticp). The sequence was alone aligned against the
downloaded ACP dataset and the non-redundant protein database of PDB and
SwissProt using online BLastp (NCBI, NIH) (Altschul et al., 1990).

2.1.2. In silico prediction of structure & function of the sequence:
Raghava group provide more online servers that aid the development of peptide drugs
especially anticancer ones. The half-life of the peptide sequence in an intestine-like
environment

could

be

predicted

using

"HLP"

webserver

(http://www.imtech.res.in/raghava/hlp/) (Sharma et al., 2014). Then, the sequence was
analyzed for toxicity using "Toxinpred" webserver which contains more than 1800
toxic peptides (http://osddlinux.osdd.net/raghava/toxinpred/) (Gupta et al., 2014).
Finally, aligning the sequence against a database of human apoptotic proteins within
cancer

context

was

done

using

"ApoCanD"

webserver

(http://crdd.osdd.net/raghava/apocand/) (Kumar & Raghava, 2016).
Using some other available online tools, the structure and function of the chosen
sequence was predicted. Using I-tasser server, provided by Zhang lab; University of
Michigan (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Zhang., 2008, Yang &
Zhang, 2015), the 3D structure of the sequence could be predicted along with
identifying top templates to which the sequence shows high structural identity. Using
COACH & COFACTOR, which are other tools provided by the same webserver, the
ligand binding site & biological function annotation of the peptide could be predicted
respectively.
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2.2. Peptide synthesis:
The 34 aa peptide was synthesized using FlexPeptide™ technology (Genscript, USA),
purified using High performance liquid chromatography (HPLC). The peptide was of
>95% purity and delivered aliquoted in a lyophilized powder form. Sterile filtered
phosphate buffered solution (PBS) was used to dissolve the peptide.

Using the

molecular calculator on Genscript Company's website, these characteristics of the
peptide were determined:

Chemical formula: C197H312N52O49

M. Wt: 4192.92 Daltons

Charge: +5 (Cationic)

2.3. Cell culture:
The cell lines used were HepG2, MCF7, HeLa & U2OS. Both MCF7, a human breast
adenocarcinoma cell line, and HepG2, a human liver cancer cell line, were purchased
from Vacsera, Egypt. HeLa, a human cervical cancer cell line, & U2OS, a human
osteosarcoma cell line, were both gifts from Dr. A. kakarougkas (Biology
Department, AUC). HepG2 was maintained in RPMI-1640 (Sigma Aldrich, USA) and
the other 3 cell lines were maintained in DMEM (Dulbecco’s Modified Eagle
Medium) (Gibco, USA) supplemented with 10% Fetal bovine serum (FBS) (Gibco,
USA) and 5% Penicillin-streptomycin antibiotic (Gibco, USA).

Cells were incubated in a humidified CO2 incubator (ShelLab, USA) adjusted at
37oC and 5% CO2. They were regularly split at 70-80% confluence. Cells were
routinely examined using an inverted microscope (Olympus IX70, USA) to detect any
morphologic changes or contamination. Viable cell counting was done for all the cells
using the Trypan blue staining method via haemocytometer (Hausser Scientific,
USA). It was a mandatory step before seeding for the MTT and annexin V/ Propidium
iodide (PI) assay.
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2.4. Cytotoxicity assay (MTT assay)
After counting, cells (HepG2, MCF7, HeLa &U2OS) were seeded in 96-well plates
(Greiner Bio-one, Germany) at a density of 2x104 viable HepG2 cells/ well and 1x104
viable cells/well for other cell lines. They were left for overnight incubation before
peptide treatment. Serial concentrations of the peptide drug (1, 10, 100, 300, 500
ug/ml) were used to treat cells. Triplicates of each condition were run, unless
otherwise specified. Fresh media was used to prepare the peptide drug serial dilutions.
In each plate, untreated cells exposed only to fresh media were used as control
cells and their absorbance values were used as the 100% viability. Additionally, some
cells in each experiment were treated with fresh media along with the solvent, used
for preparing the peptide drug (PBS), in an equivalent volume for the highest
concentration of the peptide drug in order to check whether any resultant cytotoxicity
would be due to the peptide or its solvent.
Cells were left incubated with the peptide for 24 hours before removing the drug
and adding MTT. MTT (Serva, 11 Germany) is a yellow chemical tetrazolium
compound; 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide. It reacts
with the mitochondrial dehydrogenase enzymes of viable cells producing purple
precipitate. 20ul MTT (5mg/ml) along with 100ul fresh media were added to each
well and incubated for 3-4 hours.
Then, the media with the MTT were removed and the formed crystals in each well
were solubilized using 100ul Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, USA).
Absorbance was measured using a microplate reader FLUOstar OPTIMA (BMG
LabTech, Germany). Cell vialbilty was then determined depending on the absorbance
values (at 492nm) of the test cells as a percentage of the control untreated cells (100%
viability).
The IC50 of the peptide (Median inhibitory concentration that kills 50% of the
cells) was calculated using Grpahpad Prism version 5.0 (www.graphpad.com)
(Haeley, 2005). It was calculated depending on the mean of cellular viability
percentages for the tested concentrations after log transformation of data of three
independent experiments (unless otherwise specified). Parallel experiments using
cisplatin as a standard cytotoxic drug was done for each cell line as a positive control
example of cytotoxicity. Serial concentrations of cisplatin (0.5, 1, 2, 4, 8, 16& 32
ug/ml) were used.
13

2.5. Cancer cell selectivity:
In order to test for the selectivity of the peptide, its cytotoxic activity was tested on
L929 (mouse normal fibroblast cell lines) using MTT assay in the same technique
used for the cancer cell lines using the following concentrations (0.01, 0.1, 1, 10
&100ug/ml). Cisplatin activity against L929 was also assessed using the same
concentration range used with the cancerous cell lines.

2.6. Annexin V/ Propidium Iodide (PI) assay:
All the following experiments were done on U2OS cells since it is the only cell line
that gave a well-defined statistically significant dose dependent cytotoxicity pattern in
three independent experiments. Annexin V/PI assay was performed according to
manufacturer's protocol (Thermofischer, USA) and adapted for imaging fluorescent
microscopy (Olympus IX70, USA).
Death was induced by incubating 33×104 U2OS cells in one well of a 6 well plate,
after an overnight seeding, with 200ug/ml of the peptide drug for 24 hours.
Calculations were optimized according to the seeding density and surface area for a 6
well plate. Equal number of untreated U2OS cells was seeded in another well in the
same plate to be used as negative control.

The cells were washed by PBS, trypsinized by quenching and finally centrifuged to
get a cell pellet. After trypsinization, 20ul of cell suspension was used for counting
using trypan blue to determine viability percentage of the treated and untreated cells.
The pellet was then resuspended in a volume of 1X annexin binding buffer that would
allow to have a cell count of 1x105 cells in 15ul cell suspension to be properly
deposited onto a glass slide, covered with a cover slip and visualized under the
microscope.

For each 100ul cell suspension, 10ul Annexin V conjugate (Alexa flour) and 1 ul
of PI working solution was added, incubated at room temperature in the dark for 15
minutes and then visualized under the microscope using the appropriate filters. The
fluorophore (Alexa flour AnnexinV conjugate) is a strong green fluorescent dye
excited by blue light (488nm) with an emission spectrum similar to FITC (530nm).
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Red fluorescent nucleic acid binding PI can be excited using green light (535nm) and
emits at 617nm.

2.7. Reverse Transcription-PCR (RT-PCR)
Total RNA was extracted using Trizol (Invitrogen, USA) as per manufacturer's
protocol from peptide (IC50; 100.5 ug/ml) treated U2OS cells and control untreated
cells. Extraction of RNA was followed by a quantification step in order to use
constant concentration throughout the experiments. cDNA synthesis ensued using
Revert ID™ First Strand cDNA synthesis kit (Fermentas, USA). PCR experiment for
Caspase

3

was

done

using

the

(GACCATACATGGGAGCAAGT)

following

primers

F.

Primer

R. Primer (ATCCGTACCAGAGCGAGA).

2.8. Computational assessment of OCT3 expression in studied cell lines:
Genevestigator, a high performance search engine for gene expression studies was
used (Hruz et al., 2008). The tool integrates thousands of manually curated published
microarray and RNAseq data for a reference based visualization of gene expression in
different biological contexts. OCT3 expression level was assessed in U2OS, HepG2,
MCF7 &Hela cell lines. Deficiency of molecular data on OCT6 expression made the
analysis of its expression level in different cell lines inapplicable.

2.9. Data Analysis
Statistical

analysis

was

performed

using

Grpahpad

Prism

version

5.0

(www.graphpad.com ) (Haeley, 2005). Graphical presentations were created using the
same program. All results represent the mean ± SD of three independent experiments
unless otherwise specified. One-way ANOVA was used for the statistical analysis of
multiple groups and a single variable. Unpaired t-test was used for pairwise
comparison. Results were deemed significant with P-value <0.05.

For RT-PCR experiment, densitometric analysis was done using Image-J (National
Institute of Health, USA, http://www.imagej.nih.gov/ij). Band intensities was
normalized to the intensities of the loading control (β-actin).
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Chapter 3
Results:
3.1. Computational analysis:
Out of the generated list of 59 peptide sequences with in silico predicted anticancer
activity, one 30 aa sequence with a homeodomain HMM-ID was chosen for
subsequent in silico structure analysis, synthesis and in vitro functional assessment.
The sequence was predicted as an ACP using the "AntiCP" webserver (Tyagi et al.,
2013) (Fig.3).The sequence was confirmed to be belonging to homeodomain protein
family using Blastp (Fig.4) and HMMER online webtools (http://hmmer.org/). Nearly
all resulting significant matches were homeodomain proteins of different species.
Homeodomain is a well-known family of transcription factors involved in
embryogenesis, cell differentiation and carcinogenesis in some instances (Sagan et al.,
2013).

When the sequence was alone blasted against the downloaded set of ACPs, it
showed significant alignment with one ACP namely, Bacteriocin (Fig.5). When the
sequence was analyzed for predicting its half-life in an intestine-like environment, its
half-life was predicted to be nearly 1 second with normal stability (Fig.6) and when it
was analyzed against a database of toxic peptides, it was predicted to be non-toxic
(Fig.7).

The sequence showed significant alignment with multiple apoptotic proteins when
fed into the Blastp tool of the apoptotic protein database "ApoCand". The aligned
proteins include 17 different apoptotic proteins out of the 82 proteins of the database.
The most significant of which are human BIRC2 (Baculoviral IAP repeat-containing
protein 2, UniProtKB - Q13490), human tumor necrosis factor receptor superfamily
member 1A (UniProtKB - P19438) and different caspases. Such proteins play
different roles in the numerous apoptotic pathways some of which are caspase
independent (Parthanatos).
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Figure 3: Prediction of the peptide sequence as an ACP. The sequence was
submitted to http://crdd.osdd.net/raghava/anticp/ and predicted ACP before and after
addition of the newly introduced amino acids (AAEK). The sequence exhibits
adequate amphipathic and hydrophobic properties of an ACP.

Figure 4: Blastp Alignment of the peptide sequence against PDB & SwissProt.
The sequence showed significant alignment with hundreds of homeoproteins of
different species of which are human POU transcription factors.
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Figure 5: Blastp alignment of the peptide sequence against a set of
experimentally verified ACPs. It shows significant alignment with one ACP
sequence namely Bacteriocin.

Figure 6: predicted half-life of the peptide . The tool states a short halflife of the
peptide sequence (around 1 second), though with normal stability.
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Figure 7: Predicted peptide toxicity. Peptide sequence was predicted to be nontoxic.

3.2. Peptide structure & function prediction:

Using I-Tasser, the peptide sequence was predicted to be helical (Fig.8) with the
predicted 3D model shown in Figure 9. Out of the templates showing highest structure
identity to the peptide sequence, 1ocpA (Solution structure of OCT3 POUhomeodomain (POU5F1), PDB hit) (Fig.10.A)& 2XSD (Crystal structure of the
dimeric OCT6 (POU3F1), PDB hit)(Fig.10.B) were found to show the highest
alignment score with the structure of the peptide sequence under study.

Using COACH, It was found to be nucleic acid binding which goes with the
prediction of the sequence as a homeodomain (Fig.11).COFACTOR tool could do
biological function annotation based on the anticipated 3D structure of the sequence.
Using COFACTOR, the best hit showing highest score was for Antp (Antennapedia)
which is a regulatory homeoprotein in Drosophilla that is implicated in developmental
19

regulatory pathways. Antennapedia is famous for its cell penetrating properties and
many cell penetrating peptides (CPPs) make use of its structure to enhance their
penetrability (Thoren et al., 2000).

Figure 8: Predicted peptide 2ry structure. Using I-Tasser, the 2ry structure of the
peptide sequence was found to be α-helices rich.
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Figure 9: Predicted 3D model of the peptide sequence using I-Tasser modeler.
The image depicts the 3D anticipated helical conformation of the peptide sequence.

B

A

Figure 10: Structural alignment of the predicted model with OCT3 & OCT6. The
TM-align tool of the I-Tasser server aligns the predicted model to all structures in the
Protein Databank (PDB) library. (A) Structural alignment of the predicted model of
the peptide (colored and helical) to OCT3 structure (violet ribbon). (B) Structural
alignment of the predicted model of the peptide (Colored and helical) to OCT6
structure (violet ribbon).
21

A

B

Figure 11: Ligand binding site prediction using COACH. (A) COACH tool of ITasser server infers the function of the query peptide sequence since it builds its
prediction on both sequence and structure features not only a global structural
alignment. DNA could be computationally predicted as a binding ligand to the peptide
with a good score. (B) The image depicts a model of the peptide binding to DNA
which goes with its prediction as a homeodomain. The image is drawn by Chimera
1.11.2rc.
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3.3. Cytotoxicity:

All tested cell lines showed viability reduction when treated with increasing
concentrations of the peptide. HepG2 cells showed dose dependent cytotoxicity in two
independent experiments (Fig.12).U2OS cells showed dose dependent cytotoxicity in
three independent experiments (Fig.13). Both MCF7 and HeLa (Fig.14) showed dose
dependent viability reduction in one experiment with triplicates of each condition.

Images of U2OS peptide treated cells (Fig.15) show abnormal cellular morphology
together with reduction of number of viable cells with increasing concentration of the
peptide drug. Figure 16 shows a combined graph for viability reduction of all cell
lines used. Peptide IC50 value for HepG2 cells was calculated to be 132.4ug/ml.
Peptide IC50 value for U2OS cells was calculated to be 100.5ug/ml. The IC50 for
cisplatin treated HepG2 cells was 10.37ug/ml.

A

B

Figure 12: Dose dependent cytotoxicity of peptide and cisplatin treated HepG2
cells. Six replicates of each condition were tested. (A) One way ANOVA showed a
statistical significant difference in viability between control cells (0 ug/ml) and both
300ug/ml and 500ug/ml peptide treated cells at p <0.05. (B) Higher statistical
difference in viability between control cells and (4, 8, 16 &32 ug/ml) cisplatin treated
cells at P< 0.05 is noted.
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Figure 13:

Dose dependent cytotoxicity of peptide treated U2OS cells. Eight

replicates of each condition were tested. One way ANOVA showed a high statistical
significant difference in viability between control cells (0ug/ml) and both 300ug/ml
and 500ug/ml peptide treated cells at P <0.05.

A

B

Figure 14: Dose dependent cytotoxicity of peptide treated HeLa and MCF7 cells.
Three replicates of each condition were tested. One way ANOVA was used for
statistical analysis with P<0.0.5. (A) Statistical significant difference in viability
between control untreated cells and all concentrations tested. (B) Statistical significant
difference in viability between control cells and 100ug/ml peptide treated cells and a
higher significant difference between control cells and 300ug/ml and 500ug/ml
peptide treated cells.
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Figure 15: Morphological changes of U2OS cells upon peptide treatment. Control
untreated cells (0ug/ml) show the normal morphology of U2OS cells being fusiform
in shape with intact membrane. At 100ug/ml cells started to be more elongated,
sparse with shrunken volume (red arrows). At 300ug/ml, there was a noticeable
bizarre appearance of the cells (lost normal architecture) (Green arrows). At
500ug/ml, no normal U-2 OS cells can be noted in the field which is full of round
dead cells and cells with shaggy/ragged membranes.
MCF7
U2OS

Figure 16: Variable dose dependent reduction of viability in U2OS, HepG2,
MCF7 & HeLa cell lines. Different sensitivity to peptide treatment of different cell
lines is noted with variable dose dependent cytotoxicities.
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3.4. Cancer cell selectivity
Normal murine fibroblast cell line; L929 showed reduction of viability upon peptide
treatment but not in a dose dependent manner. Evident cytotoxicity started at
100ug/ml concentration (Fig.17A). No statistical significant difference was noted
among different concentrations and control untreated cells and IC50 was predicted,
using Prism 5, to be above the highest concentration tested. On the other hand, L929
showed dose dependent cytotoxicity when treated with cisplatin with an IC50 value of
21.8ug/ml (Fig. 17B).

A

B

Figure 17: Effect of peptide and cisplatin on L929 cells. (A) No pattern of
cytotoxicity could be observed with increasing concentrations of the peptide on L929
cells. (B) L929 show statistically significant dose dependent reduction of viability
when treated with cisplatin with an IC50 value of 21.8ug/ml.

3.5. Annexin V/PI assay:

Annexin, a human anticoagulant, has a high affinity to bind Phosphatidyl serine (PS)
that gets externalized on the surface of early apoptotic cells. Thus, Alexa fluorophore
conjugated Annexin can easily identify apoptotic cells by appearing green when
excited by blue light. The red fluorescent DNA binding PI can't penetrate live or early
apoptotic cells. It binds tightly to DNA of necrotic and late apoptotic cells staining
them with red fluorescence when excited by green light.
26

Untreated U2OS cells, showed low number of green, red and green/red cells as
well as low fluorescence intensity (Fig. 18). Images of peptide treated U2OS cells
shows that most of the cells, appearing in the field, are stained green as a sign of
apoptosis. Red fluorescence was not detected alone, but it was always emitted along
with green fluorescence indicating necrotic/apoptotic cells (Fig.19). Higher
magnification images (20X) show morphological changes of some cells along with
illustration of membrane disassembly into apoptotic bodies with no signal detected
from completely disrupted cell (Fig. 20).

Figure18: Annexin V/PI assay of untreated U2OS cells. The field shows low
number of stained dead cells (White circles).

Figure 19: Annexin V/PI assay of peptide treated U2OS cells (10X
magnification). Field shows dominance of green stained cells indicating apoptotic
cells.
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A

B
B

C
Figure 20: Annexin V/ PI Assay of peptide treated U2OS cells (20X
magnification). (A) Yellow circles highlight viable cells, green circles highlight
apoptotic cells and red circles highlight apoptotic/necrotic cells. (B) Almost all of the
cells in the filed shown are stained green indicating apoptosis. (C) Arrow point to
budding from a disrupted cell that is most likely to be apoptotic bodies. It’s assumed
that the cell is completely disrupted that it didn't take up any dye.
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3.6. RT- PCR
Caspase 3 shows non-statistically significant higher expression in peptide treated
U2OS cells versus control cells (Fig.21). β-actin was used as a housekeeping gene and
it shows comparable expression in the 2 samples.

Figure 21: RNA expression analysis of Caspase 3 in untreated vs peptide treated
U2OS cells. It shows over expression in peptide treated cells

3.7. Computational assessment of OCT3 expression in studied cell lines:

Using the cell lines tool of Genevestigator, the expression level of OCT3 (POU5F1)
could be visualized in a large collection of cell lines including U2OS, HepG2, MCF7
& HeLa. Its expression level was found to vary among the cell lines under study
(Fig.22).
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Figure 22: OCT3 (POU5F1) expression level in U2OS, HepG2, MCF7 &HeLa
cell lines. Computational analysis of OCT3 expression in different cell lines using
Genevestigator webtool was done. It demonstrates highest OCT3 expression, among
cell lines under study, in MCF7 and lowest in U2OS. HeLa and HeLa derived cell
lines show slightly variable OCT3 expression, but still higher than that in U2OS.
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Chapter 4
Discussion

4.1. Computational Analysis:
The in silico prediction of the peptide sequence as a cationic, amphipathic, non-toxic
and stable ACP was a strong start of the subsequent structure analysis and functional
validation of the potential anticancer activity. Besides its online computational
prediction as an ACP (Fig. 3), it showed significant alignment, using Blastp, with
bacteriocins (Fig. 5) which encompass a family of bacterial cationic peptide toxins
that have lately shown potent cytotoxic and apoptosis inducing effects in many cancer
cells (Nguyen & Nguyen, 2016, Kaur & Kaur, 2015).

The peptide structure was predicted to be helical (Fig. 8 & 9) which goes with its
prediction as an ACP as the helical conformation is characteristic of many studied
ACPs and was confirmed essential for their interaction with the cancer cell membrane
(Zhang et al., 2010, Chen et al., 2014).

The half-life of the peptide in an intestine like environment was computationally
predicted to be nearly 1 second (Fig. 6) which is quite short and indicates its
susceptibility to proteolytic degradation after systemic administration. Its stability
should be further assessed using incubation with biological matrices e.g. blood,
serum, stimulated gastric or intestinal fluid in order to observe its kinetic profile and
degradation products (Di, 2015). However, from another point of view serum
instability won't affect its topical or intralesional uses may be for various skin cancers.
Predicting the peptide non-toxic (Fig. 7) favors any subsequent planned in vivo
testing.

Aligning the peptide sequence to a homeodomain superfamily using Blastp (Fig. 4)
and modeling its peptide structure against PDB, using I Tasser, and its significant
alignment with OCT3 and OCT6 homeodomains (Fig. 10) confirm our in silico
prediction of it as a homeodomain which gives a solid ground for our in silico results.
Moreover, COACH predicted its ligand binding site to be DNA (Fig. 11) which is
valid for the homeodomain family of transcription factors.
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COFACTOR annotated its biological function to Antennapedia (AntP); a regulatory
homedomain in Drosophila (Fig. 12). AntP is famous now for its use as a fusion cell
penetrating peptide (Penetratin) to carry cargo molecules to the interior of the cells
(Thoren et al., 2000). Annotating the function of our peptide to Antp suggests it might
easily penetrate to the inside of the cells. Following translocation into the cell, it may
either initiate an intracellular death cascade or restore the function of downregulated
or compete with an upregulated OCT3 or OCT6 according to the carcinogenic events
in the studied cancer.

The sequence and structural similarity to OCT3 favors the peptide, if penetrable to
the cell membrane, to be acting as a competitor to OCT3 that is found to be
upregulated and involved in carcinogenesis of bone, liver, breast and cervix (Fujino et
al., 2010, Dong et al., 2012, Wang et al., 2003, Wang et al, 2013a).

4.2. Cytotoxicity

The peptide exerted a cytotoxic effect against all tested cell lines (HepG2, U2OS,
MCF7 and HeLa) in a dose dependent manner (Fig. 12, 13 & 14). The variable
sensitivity of the cell lines (Fig.16) to peptide treatment using the same concentrations
can be explained as previously discussed in the review chapter by the varied
membrane lipid composition of each cell line which dictates peptide preference and
affects its conformation upon contact with the membrane (Eliassen et al., 2006,
Gasper et al., 2015). Another explanation might be the differential expression of
OCT3 in studied cancers, which is predicted from computational analysis of
microarray and RNAseq data (Fig. 22), if the proposed mechanism of action would be
interference with OCT3 function. Performing Chromatin Immunoprecipitation (ChIP)
assay may help prove this proposition.

Under low concentrations (1 & 10 ug/ml), U2OS and HepG2 showed comparable
viability reduction (Fig. 16). Starting from 100 ug/ml concentration on, U2OS
displayed more viability reduction than HepG2 (Fig. 16). This can be explained
according to (Wang et al., 2013b) where it was found that there was a concentration
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dependent variation in the anticancer activity of the peptide under study (temporin1CEa).

They found temporin-1CEa at certain low concentration, with its helical
amphipathic conformation, to get bound to the cell membrane with subsequent loss of
its integrity. At higher concentrations, it could initiate a caspase dependent apoptotic
cascade. They concluded that accumulating concentrations of the peptide on the
membrane above a certain threshold induces its damage with subsequent translocation
of temporin to the inside of the cells initiating apoptosis and accelerating cell death.
This might be the explanation for the increased sensitivity of U2OS to peptide
concentrations≥100ug/ml more than HepG2 as it might had then displayed an
additional mechanism of action in U2OS cells and not in HepG2 cells.

HeLa cells (Fig. 14A) show statistically significant viability reduction even at low
concentrations that doesn't go much down as peptide concentrations go up. This might
be explained by the peptide acting only through an early death inducing mechanism of
action e.g. membrane damage and necrosis and so any additive concentrations would
accumulate and wouldn't enhance its activity. MCF7 cells (Fig. 14B) show
comparable viability reduction at low concentrations (1, 10, 100 ug.ml) that abruptly
goes down at 300 & 500ug/ml concentrations. This might be due a dual mechanism of
action of the peptide in MCF7 cells.

Illustrated in the review chapter two peptide examples (HNP-1 &Lcfin-B) acting
through different mechanisms in different cancers. The difference in timing of each
mechanism might explain the variability in cytotoxicity results in different cancer
contexts. For example, peptides causing membrane disassembly would show faster
cytotoxicity than those causing DNA damage or synthesis inhibition. Necrotic
peptides show earlier results than those causing apoptosis. Thus, testing cytotoxicities
at different incubation times and using a wider range of concentrations might provide
a clue for the mechanism of action in each cell line.

An accurate way to assess selectivity is to monitor the IC50 of the peptide against
a normal and a cancerous cell lines and to monitor the IC50 of a standard
chemotherapeutic drug against the same cell lines. Then a selectivity index (SI) would
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be calculated for each drug by dividing the IC50 of the normal cell line by that of the
cancerous one. If the index of the experimental drug is higher than that of the standard
drug, then it's likely to be a more selective potent drug candidate.

Peptide treated L929 cells (Fig.17A) showed unapparent pattern of cytotoxicity
under the range of concentrations tested from which calculation of an IC50 denoted a
wide range that would go higher than the highest concentration tested (100ug/ml).
While a cisplatin SI could be calculated (Fig. 12B, 17B) as follows:

IC50 of cisplatin on L929 cells

21.8

SI =

=
IC50 of cisplatin on HepG2 cells

= 2.1
10.37

Since the IC50 of peptide treated HepG2 cells = 132ug/ml and apparently the IC50
for peptide treated L929 cells would go much higher. We suppose its SI would be
comparable if not higher to cisplatin.

Mole, in chemistry, is the standard measurement of amount. Thus, converting the
gram concentrations applied throughout this study into their molar equivalents would
reveal another aspect of the cytotoxic activity of the peptide drug and cisplatin
depending on the difference of their molar masses. The molar mass of the peptide
drug equals 4192.9042 gm/mol and that of cisplatin equals 300.04 gm/mol.

Using available online molarity to mass converting calculators, we could find that
the highest peptide concentration (500ug/ml) tested equals 119.2uM and the highest
cisplatin concentration (32ug/ml) tested equals 106.6uM. The peptide IC50 on HepG2
(132.8ug/ml) equals 31.6uM and the cisplatin IC50 on HepG2 cells (10.37ug/ml)
equals 34.5uM which in terms of molarity is much higher than that of the peptide drug
despite being much lower when calculated in grams.

4.3. Apoptosis or Necrosis

Morphological changes of peptide treated U2OS cells (Fig.15) show evident
shrinkage of cells upon treatment with 100ug/ml but with preserved architecture.
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300ug/ml peptide concentration caused more bizarre appearance with shredded
membranes of a high proportion of cells. At 500ug/ml concentration, no intact cells
could be noted. These changes are consistent with an apoptotic death event in which
shrinkage and membrane disintegration are main key events.

Figure 18 shows a few necrotic/apoptotic cells in the field of control untreated
U2OS cells compared to figure 19 and figure 20B, where almost all cells are stained
green indicating apoptotic cells with very few green/red cells. Higher magnification,
20X, (Fig. 20C) shows a cell ghost with disintegrated budding membrane into
apoptotic bodies that did not even give a green signal, may be due to complete
damage of its membrane. These results support an apoptotic mode of action.

The morphological changes depicted in figure 15 with absence of necrotic cell
swelling, membrane blebbing and cellular rupture diverted our attention from necrosis
as a possible mechanism of cell death. However, more electron microscope based
morphological studies of apoptosis related nuclear and mitochondrial changes must be
done to be more confident of apoptosis occurrence. Mitochondrial transmembrane
potential and ATP level should be assessed. Fluorescence conjugated peptide would
be a useful approach for investigating where it localizes inside the cell.

4.4. RNA expression analysis

Increased expression of Caspase 3, an initiator caspase, in peptide treated U2OS cells
(Fig.21) supports the apoptotic mode of action as well. However, being nonstatistically significant along with the complex molecular nature of apoptosis
pathways indicates that more studies to confirm and detect which pathway was
involved should be done. DNA laddering and expression of other effector caspases,
apoptotic markers e.g. Bcl2, Bax, IAPs and proliferation markers should be done.

Wang et al., (2013b) demonstrated that Temporin-1CEa mediated its effect in a
caspase dependent manner at certain concentrations and in a caspase independent
manner at other concentrations. Since, in our case RNA expression analysis was done
for IC50 treated U2OS cells, it's recommended to be done for cells at various dose
conditions and various incubation times as well.
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Conclusion & Future recommendations

Conclusion

In summary, we could conclude that we've developed a cationic amphipathic
cytotoxic peptide with a potential to be developed into an ACP drug lead. The peptide
has an in silico sequence and structural similarity to homeoproteins. Its cytotoxicity
can be either due to a non-specific selective membranolytic effect on cancer cells
being cationic helical and amphipathic, which supports its non-specific electrostatic
interaction with cancer cell membranes, or another non-membranolytic mechanism.
Moreover, we could conclude that most probably the peptide is adopting a different
mechanism of action in each cell line and may be more than one in the same cell line.

The results could support two proposed mechanisms of action other than
membranolysis. It might either compete with OCT3 function or be an apoptosis
inducing peptide. Sequence and structural similarity to OCT3 homeodomain, being
biologically annotated to AntP cell penetrating peptide together with the notion of
OCT3 as an upregulated and carcinogenic effector in the studied cancers support the
hypothesis that the peptide may be acting through competitive inhibition of OCT3.

The apoptotic mechanism of action is supported by the cytotoxicity results, evident
annexin staining and over expression of Capsase 3 in peptide treated cells. No definite
pathway could be outlined depending on this data. The in silico alignment of the
peptide to several apoptotic proteins, implicated in different pathways, support the in
vitro results. The non-statistical significant overexpression of Caspase 3 doesn't
disprove our hypothesis since some apoptosis mechanisms are caspase independent
(parthanatos).
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Future recommendations:

Developing a peptide drug is challenging but quite rewarding. In order to develop an
effective and selective oncolytic peptide, precise data on its structure, biophysical
properties and mode of action must be obtained. There is a long avenue of basic
research and preclinical optimization to be done before a peptide can be claimed to be
an ACP.

Bioinformaticians are doing a great effort to compile data about the newly
introduced peptide based drugs in general and ACPs in particular into well-organized
publicly available databases. Those web-servers are supported by user friendly tools
to manipulate peptide sequence and predict its properties and hence its activity. It
would be auxiliary to develop webservers for designing and modeling peptides against
3D models of definite cellular targets (peptide specific docking servers) to optimize
peptide based targeted therapy approaches. Moreover, softwares to predict enzymatic
cleavage sites of peptides would greatly help directed modification strategies, during
peptide synthesis, to optimize peptide stability.

There are upcoming duties for chemists interested in the field of ACPs to develop
cheap and efficient methods to modify peptide sequences in a way that would
overcome the obstacles of peptide serum instability and rapid plasma clearance.
However, these modifications should not disturb the basic required conformation and
properties essential for the anticancer activity of the peptide.

The future of the field of ACPs is highly dependent on how successfully growing
the basic research errand. Precise structure determination tools such as mass
spectrometry and nuclear magnetic resonance should be available for every ACP
oriented research. More imaging tools such as scanning electron microscope,
transmission electron microscope and confocal microscope should be at hand for
accurate determination of the cellular death morphologic events.
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Cytotoxicity analysis at different time points and a wider concentration range
should be investigated for early and late cellular death modes of actions. The peptide
should be tested against a bigger panel of cell lines. Analysis of cytotoxicity using
more than one assay such as MTT assay, LDH release assay....etc must be done.
Testing the expression of apoptotic and necrotic markers, DNA fragmentation
occurrence and other apoptotic studies must be a part of every research aiming to
develop an ACP lead.

Finally, more confirmatory studies are essentially needed to confirm our
preliminary results. More ACPs oriented studies are needed to exploit this rich source
of selective, easy to synthesize and effective weapon to be added to the anticancer
arsenal.
.
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